SEQENS, a manufacturer of active ingredients and pharmaceutical intermediates, is making a multi-million-dollar investment in its R&D lab in Devens, MA. The improvements aim to ensure the new facility will operate at the highest standards of safety and quality, and increase R&D capability and productivity in the U.S. The project is expected to be complete in October 2022.   The investment in Devens strengthens the company’s U.S. operations—which also includes a sales office and contrac...